peptide half-life comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
Reported molecular weight is approximately 4113.6 daltons for the free base, and the peptide is supplied as a lyophilized powder or in buffered liquid form depending on the intended use. It is freely soluble in water when formulated with appropriate excipients, though the unconjugated peptide shows limited stability at neutral pH over long periods. Analytical characterization typically relies on reversed-phase high-performance liquid chromatography and mass spectrometry. Purity specifications for research-grade material commonly exceed ninety-five percent by area. Isotopic and impurity profiles differ between suppliers.
Two principal therapeutic variants exist under separate regulatory filings, one indicated for glycemic control in type 2 diabetes and one for chronic weight management. Both use the same active molecule; differences lie in formulation strength, titration schedule, and labeling. Regulatory agencies in the United States and European Union approved injectable forms in 2017 and 2018 respectively. An oral tablet formulation received approval later, using a carrier molecule to enhance absorption across the gastric epithelium. Labeling differs by jurisdiction and by indication.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released by intestinal L cells after food intake. The natural hormone acts on pancreatic and central receptors but is degraded within minutes by dipeptidyl peptidase-4 and other peptidases. Semaglutide belongs to the class of long-acting GLP-1 receptor agonists, a group distinguished by structural changes that slow breakdown and extend circulation time. Its development followed earlier short-acting analogues and reflects a general strategy in peptide drug design: preserve receptor activity while blocking proteolytic clearance.
Three structural changes define the molecule. At position 8 an alpha-aminoisobutyric acid residue replaces alanine, which blocks dipeptidyl peptidase-4 cleavage. At position 34 arginine replaces lysine, and at position 26 a lysine carries a C18 fatty diacid attached through a short linker. The fatty chain binds serum albumin, and this albumin association reduces renal filtration and enzymatic attack. The unchanged backbone retains the receptor contacts that produce signalling. The free base has the formula C187H291N45O59 and a molecular weight near 4114 daltons.
| Property | Value | Notes |
|---|---|---|
| Molecular formula (free base) | C187H291N45O59 | Approximate; salt and hydrate forms differ |
| Molecular weight | ~4113.6 Da | Varies with counterion and hydration |
| Appearance | White to off-white powder | Lyophilized research material |
| Solubility class | Freely soluble in water | As formulated; native peptide less stable near neutral pH |
| Typical storage | 2 to 8 degrees Celsius | Protect from light; avoid repeated freeze-thaw |
Activation of the GLP-1 receptor couples to Gs signalling and raises intracellular cyclic AMP in pancreatic beta cells. The resulting insulin release depends on prevailing glucose concentrations, so the effect is greater when glucose is elevated. Receptor engagement also suppresses glucagon secretion and slows gastric emptying, which flattens post-meal glucose excursions. In the central nervous system, signalling in hypothalamic and brainstem regions is associated with reduced appetite and lower energy intake. Studies continue to examine effects on cardiac, renal and hepatic endpoints; whether those benefits are independent of weight change remains an open question.
Clinical development of this compound followed earlier short-acting GLP-1 analogues that required frequent injection. Once-weekly subcutaneous formulations entered use after 2017, and an oral formulation using a permeation enhancer later became available. The oral version pairs the peptide with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, a carrier that improves uptake across the gastric epithelium. Interest has expanded from glycaemic control into weight management and metabolic liver disease. Regulatory status and approved indications differ between countries, and the product remains subject to ongoing safety monitoring.
Lyophilized semaglutide powder is typically held at minus twenty degrees Celsius for long-term storage. At that temperature, solid-state degradation reactions proceed slowly and the peptide remains intact for extended periods. Repeated freeze-thaw cycles are best avoided because they promote aggregation and can shift the proportion of monomeric peptide present. Working aliquots are often prepared so that each portion is thawed only once, and desiccant is placed inside the vial to limit moisture uptake.
Identity and purity are usually assessed by reverse-phase high-performance liquid chromatography coupled to mass spectrometry. Retention time and observed mass are compared against a reference standard run under identical conditions. Impurity profiles reveal deamidation products, oxidized methionine variants, and truncated fragments that arise during synthesis or storage. Peptide mapping through enzymatic digestion confirms the primary sequence, while amino acid analysis offers an independent check on overall composition.
Stability studies examine how temperature, pH, and moisture influence degradation rates over time. In aqueous solution, hydrolysis and deamidation accelerate as pH moves away from mildly acidic conditions. Light exposure and residual metal ions can also trigger oxidation of susceptible residues. Accelerated aging at elevated temperature is used to estimate shelf life, though extrapolation to room temperature carries uncertainty because individual degradation pathways do not always scale predictably.
Stilton blue cheese was first sold in the village of Stilton in England, but there is little evidence it was ever made there. Stilton cheese is made from pasteurized milk; a similar, less commonly found, blue cheese made from raw milk and without factory-produced rennet is Stichelton. In addition to being inoculated with Penicillium roqueforti to give it the blue vein characteristic, research has shown that other microbiota which are relatives of Lactococcus lactis, Enterococcus faecalis, Lactobacillus plantarum, Latilactobacillus curvatus, Leuconostoc mesenteroides, Staphylococcus equorum, and Staphylococcus sp. can also be found in blue Stilton cheese. Some important microbiota contribute to the aromatic profile such as those of the Lactobacillus genus due to their production of volatile compounds. During ripening, free fatty acids increase in amount, which contributes to the characteristic flavor of blue cheeses due to fat breakdown by Penicillium roqueforti. There is also uninoculated white Stilton cheese.
However, it is notable that the anabolic steroid methyltestosterone, which benorterone differs from in chemical structure only by the removal of a carbon atom in the B ring, is aromatized into the estrogen methylestradiol and has potent estrogenic activity. Estrogens are antigonadotropic similarly to androgens and progestogens and are likewise able to suppress testosterone levels. In accordance, the compound corresponding to what would be the aromatized form of benorterone, 17α-methyl-B-norestradiol, has been described and has been reported to possess estrogenic activity, although the aromatization of benorterone has not been assessed. A couple of studies found that prothrombin levels decreased by 50% in some patients treated with benorterone, although a causal relationship between this change and benorterone could not be shown.
Meinrad Busslinger (born 30 July 1952) is a biochemist and immunologist, renown for his work on B cells. He is a Senior Scientist and Scientific Deputy Director of the Research Institute of Molecular Pathology (IMP) in Vienna, Austria.
Sources: en.wikipedia.org
== Effect on animals == Possible effects on animals are endocrine disruption, reproductive and immune dysfunction and cancer. A remarkable phenomenon that has been demonstrated in numerous animal studies is that repeated exposure to organophosphates causes the mammals to be less susceptible to the toxic effects of the AChE inhibitors, even though cholinesterase activities are not normal. This phenomenon is caused by the excess of agonists (ACh) within the synapse, ultimately leading to a down-regulation of cholinergic receptors. Consequently, a given concentration of ACh within the synapse causes fewer receptors to be available, which then causes a lower response. Studies have shown that the AChEs in fish brains are more prone to organophosphates than amphibian brains. This can be explained by the affinity for AzM and rate of phosphorylation of the enzymes. Frog brain AChE has for example a lower affinity for AzM and a slower rate of phosphorylation than fish brain AChE. The effects on amphibians are “reduced size, notochord bending, abnormal pigmentation, defective gut and gills, swimming in circles, body shortening, and impaired growth”. In sea urchins, specifically the Paracentrotus lividus, AzM modifies the cytoskeleton assembly at high concentrations and can alter the deposition of the skeleton of the larva at low concentrations. In mice, AzM causes weight loss, inhibits brain cholinesterase (ChE) and lowers the food consumption of the mice. A decrease of 45-50% of brain ChE is lethal in mice. Also in earthworms and rats, AzM decreases AChE activity.
=== 1980–2000: Development of Viagra, Zoloft, and Lipitor === In 1981, the company received approval for Diflucan (fluconazole), the first oral treatment for severe fungal infections including candidiasis, blastomycosis, coccidiodomycosis, cryptococcosis, histoplasmosis, dermatophytosis, and pityriasis versicolor. In 1986, Pfizer acquired the worldwide rights to Zithromax (azithromycin), a macrolide antibiotic that is recommended by the Infectious Disease Society of America as a first line treatment for certain cases of community-acquired pneumonia, from Pliva. In 1989, Pfizer scientists Peter Dunn and Albert Wood created Viagra (sildenafil) for treating high blood pressure and angina, a chest pain associated with coronary artery disease. In 1991, it was patented in the United Kingdom as a heart medication. Early trials for the medication showed that it did not work for the treatment of heart disease, but volunteers in the clinical trials had increased erections several days after taking the drug. It was patented in the United States in 1996 and received approval by the Food and Drug Administration in March 1998. In December 1998, Pfizer hired Bob Dole as a spokesperson for the drug. The patents for Viagra expired in 2020. In 1991, William C. Steere, Jr. became CEO, succeeding Edmund T. Pratt Jr. In 1991 Pfizer also began marketing Zoloft (sertraline), an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class developed nine years earlier by Pfizer chemists Kenneth Koe and Willard Welch.
== Further reading == Press Conference by professor Samuel S. Epstein M.D. 1999-05-31 World Trade Organization (2000). Dispute Settlement Reports 1998. Cambridge University Press. p. 79. ISBN 0-521-78895-1. Galbraith, H. (December 2002). "Hormones in international meat production: biological, sociological and consumer issues". Nutrition Research Reviews. 15 (2). CABI Publishing: 293–314. doi:10.1079/NRR200246. PMID 19087409. M. Ellin Doyle. "Human Safety of Hormone Implants Used to Promote Growth in Cattle". National Cattlemen's Foundation. Archived from the original (Microsoft Word) on 7 May 2006. J. J. Kastner & R. K. Pawsey (29 November 2001). "Harmonising sanitary measures and resolving trade disputes through the WTO–SPS framework. Part I: a case study of the US–EU hormone-treated beef dispute" (PDF). Food Control. 13. Elsevier Science Ltd.: 49–55. doi:10.1016/S0956-7135(01)00023-8. Archived from the original (PDF) on 21 May 2004. Tim Josling; Donna Roberts & Ayesha Hassan (12 April 2000). "The Beef-Hormone Dispute and its Implications for Trade Policy" (PDF). Stanford University. Archived from the original (PDF) on 11 June 2007. Grace Skogstad (September 2001). "The WTO and Food Safety Regulatory Policy Innovation in the European Union". Journal of Common Market Studies. 39 (3): 485–505. doi:10.1111/1468-5965.00300. Christina L. Davis (2003). "Battles over Beef: The Beef Hormone Dispute". Food Fights Over Free Trade: How International Institutions Promote Agricultural Trade Liberalization. Princeton University Press. pp. 321–337. ISBN 0-691-11505-2.
In 1299, according to the Malay Annals, the Kingdom of Singapura was founded on the island by Sang Nila Utama. Although the historicity of the accounts as given in the Malay Annals is the subject of academic debates, it is nevertheless known from various documents that Singapore in the 14th century, then known as Temasek, was a trading port under the influence of both the Majapahit Empire and the Siamese kingdoms, and was a part of the Indosphere. These Indianised kingdoms were characterised by surprising resilience, political integrity and administrative stability. Historical sources also indicate that around the end of the 14th century, its ruler Parameswara was attacked by either the Majapahit or the Siamese, forcing him to move to Malacca where he founded the Sultanate of Malacca. Archaeological evidence suggests that the main settlement on Fort Canning Hill was abandoned around this time, although a small trading settlement continued in Singapore for some time afterwards. In 1613, Portuguese raiders burned down the settlement, and the island faded into obscurity for the next two centuries. By then, Singapore was nominally part of the Johor Sultanate. The wider maritime region and much trade was under Dutch control for the following period after the 1641 Dutch conquest of Malacca.
Sources: en.wikipedia.org
It is a modified version of the natural hormone, with three amino acid changes and a fatty acid side chain added. These edits extend its half-life from minutes to about one week. The core receptor activity is retained.
Both deliver the same active peptide and act on the same receptor. The tablet includes an absorption enhancer because peptides are poorly taken up intact from the gut. Bioavailability of the oral route is substantially lower, so the two are not dose-equivalent.
No, it is entirely synthetic and does not occur in nature. Native GLP-1 is produced in the gut and pancreas, but the analog is manufactured by chemical synthesis or recombinant methods. Traces of the analog are not expected in people who never received it.
Native GLP-1 is a short-lived peptide cleared within one to two minutes by dipeptidyl peptidase-4 and related enzymes. Semaglutide keeps the receptor-binding backbone but adds substitutions and a lipid chain. These changes block the main cleavage site and allow reversible albumin binding, extending the half-life to roughly 165 hours.